Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alpharma

This article was originally published in The Tan Sheet

Executive Summary

Company will ship generic Cromolyn Sodium Nasal Solution USP to several major drugstores in the first half of August, firm says. Alpharma received final approval of ANDA 74-800 for its Nasalcrom equivalent July 26 and is second private labeler to receive FDA clearance; Bausch & Lomb's generic cromolyn sodium was approved in early July (1"The Tan Sheet" July 9, p. 28). Pharmacia's Nasalcrom lost marketing exclusivity July 3, 2000 after receiving six months of pediatric exclusivity

You may also be interested in...



Pfizer BenaMist Launch Delayed By Manufacturing Issues

Pfizer Consumer Healthcare's launch of its BenaMist Allergy Prevention Nasal Spray is being delayed due to production problems faced by contract manufacturer Alpharma, Pfizer said

Pfizer BenaMist Launch Delayed By Manufacturing Issues

Pfizer Consumer Healthcare's launch of its BenaMist Allergy Prevention Nasal Spray is being delayed due to production problems faced by contract manufacturer Alpharma, Pfizer said

Pfizer BenaMist Launch Delayed By Manufacturing Issues

Pfizer Consumer Healthcare's launch of its BenaMist Allergy Prevention Nasal Spray is being delayed due to production problems faced by contract manufacturer Alpharma, Pfizer said

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel